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Submission to the Committee 
on the Ethics of Gene Therapy 
by the Joint Ethico-Medical Committee of the 
Catholic Union of Great Britain and the Guild of Catholic Doctors 
The Catholic Union is a non-affiliated lay Organisation under the 
Presidency of His Grace the Duke of Norfolk and The Guild of Catholic 
Doctors is an autonomous Bod y of approximate ly 1.000 practising British 
Doctors. This Submisson is made by the Joint Ethico-Medical Committee 
o n behalf of the two Bodies. 
As Catholics we have a tradition of affirming human dignity under 
contemporary co nditions and we endorse; the generally accepted ethical 
principles of justice and beneficence, and the autonomy of patients . 
Although scientific di scove ry can be a legitimate end in itself where Man is 
concerned we accept the principles of the Helsinki Declaration which state 
inter alia: - "Concern for the interest of the subject must always prevail 
over the interests of science and society" (Principle /.5). 
GENE THERAPY 
We consider this de ve lopment to be exceedingly important and follow 
with interest the decisions ta king place between Clinicians and Scientists in 
this field both in the country and overseas. We hope that new therapeutic 
possibilities will arise which could benefit patients, but there are dangers. 
As a result of the science of molecular biology four thousa nd single gene 
disorders have so far been id entified. In time a complete decoding of the 
human genome may revea l the genetic predisposition for other diseases 
including some which are multi-genetic . 
Advances in conventional treatment have become available in recent 
times, leading to symptomatic relief from some 12% of the inherited 
diseases (e.g. Phenyl-ketonuria) and the partial relief of another 40% (e.g. 
Cystic Fibrosis). slightly less than half of the known inherited diseases 
cannot be substantially relieved by conventional medicine. 
Tissue and organ transplantation may improve these figures. Examples 
a re successful marrow tra nsp lantation for some of the inherited anaemias 
a nd, more recentl y, lung transplantation for end stage sufferers of cystic 
fibrosis. (Royal College of Physicians Conference on 'Gene Therapy' 1990). 
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Clinical gene therapy is aimed at the replacement of d efecti ve genes and is 
similar to organ transplantation. This technique can be applied to somatic 
cells or to germ-line cell s. The consequences of germ line cell therapy would 
be that the alterations would be transmitted to progen y, thus making a 
profound ethical difference from somat ic cell therapy. 
SINGLE GENE DISORDERS 
For successful gene modification it is necessary that: 
I. the gene and its regulatory region has been isolated. 
2. the target ce ll for genetic modifica tion is accessible. 
3. a safe transfer syste m must be fo und . and 
4 . th ere must be a reasonable prospect of th e lo ng te rm surviva l of the new ce ll 
popula tion. with it s beneficial exp ress ion . 
We understand that so me of the disorders which might be treated in thi s 
way when suitable techniques have been perfected include: 
Some congenital immu ne deficiency di so rders 
Thallassaemia 
Phenylke tonuria 
Gauchers di sease 
Lesc h-N yhan di sease. 
This is only the beginning of what could prove to be a substantial list. 
ETHICAL CONSIDER A TIONS OF SOMA TIC CELL 
GENE THERAPY 
In ge neral terms, the ethical considerations are similar to those of tissue 
or organ tra nspla ntati o n . There must be a ba la nce between risks and 
benefits. and after the techniques have bee n perfected using animal model s. 
including Public Health aspects. they may become applicable to humans. 
We acknowledge that the first di so rd ers to be trea ted are th ose which are 
currently fatal or profoundly crippling but ca nnot exclude the poss ibilit y 
that. with time. o ther conditions ma y legi tima tel y benefit from ge ne 
modification. An example of thi s co uld be hae m o phili a which ca n a lread y 
be treated successfull y. The ri sk Ibenefit ra ti o for ge ne therapy would ha ve 
to be bett er than tha t o f the present treatme nt. 
In this , it is not ed that the pa tient s will. for th e most pa rt. be in a position 
to give consent o n their own behalf. or. wi th children. by proxy. In genera l. 
it seems to us. th e giving of co nsent o n behalf of a minor wo uld require a 
hi gher degree of ass ura nce of success and benefic ia l outcome than that 
w hich would justify consent by adults on th eir ow n behalf. It is neither 
et hica l nor lega l for a parent to give consent o n behalf of a child to any 
procedure which is not in the ch ild 's own int erest. We consider that th is. in 
practice. exc ludes the ap plicatio n of ge ne therapy for reasons (such as 
cosmetic or aesthetic) other than for th e treatment of pathological 
cond iti ons. 
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It also seems to us not inconceivable that children could sue parents for 
any damage done to them, as an individual , as a result of an intervention by 
t he parent. 
ETHICAL CONSIDERATIONS OF GERM LINE CELL 
GENE THERAPY 
There are major scientific and ethical differences between somatic (non-
reproducible) and germ line (reproducible) therapy. The latter results in a 
permanent alteration of an individual's genetic composition which would 
be transmitted by them to future generations. The first and obvious factor is 
that such a step is irreversible. . 
A particular problem relating to autonomy arises from the impossibility 
of obtaining the consent of future or developing affected individuals. Even 
if an assumption is made that individuals would wish to be spared a disease , 
t he re would need to be a wide measure of agreement in Society that only 
those diseases of the most crippling nature would justify the risks of 
permanently altering the human genome. 
We also consider that alteration of the human genome, which would 
affect future generations, would be unjust as it denies such generations their 
autonomy and may not accord with full human dignity. In other words, 
eve n if it could be foreseen that germ-line cell therapy might become an 
acceptable form of treatment for disease, such that the parents might be 
entitled to consent to it for the child's benefit and to its own good, there 
remains the impossibilit y of obtaining the consent of future generations to 
alterations affecting the human 'genetic library'. We have no right to 
assume that their wishes necessarily correspond with our own. and it 
thereby becomes impossible to envisage a situation where we would be 
en titled to assume their consent. 
The long term effects of alterations to the genome cannot be foretold. 
The removal of defective genes (such as sickle cell anaemia) might lower 
community protection factors (in this case against malaria). 
In addition. whilst some of the common disorders , such as diabetes, 
atherosclerosis and hypertension. which are known to have genetic 
predispositions. could arguably be alleviated by gene therapy we consider 
thi s to be unjustifiable when alternative therapy or alterations in life style 
achieve comparable results. 
Further difficulties are like ly to arise with germ line therapy if, as it seems 
likely. it would be inevitably linked with screening during antenatal 
development with a view to terminating those pregnancies in which the 
genetic transfer appeared imperfec t. We think it probable that at the early 
stages of germ line gene therapy such screening might be a condition of the 
patient being accepted for treatment. This would, of itself. be incompatible 
with a woman's autonomy and should not be required. although there is at 
prese nt no experimental basis for treating polygenetic conditions, there is at 
least a theoretical possib ilit y that this could be used not only for the 
16 Linacre Quarterly 
treatment of maladies but for such manipUlations as attempts to improve 
human intelligence , physique or life span. this would be analagous to 
eugenics which is open to grave abuse and could lead to great human 
injustice . We doubt if there ever could be agreement in Society on those 
human characteristics which should be enhanced or those which should be 
eliminated and attempts to take scientific control of human evolution seem 
to be little more than scientific hubris. We have already expressed our view 
that such attempts would be ethically unacceptable. 
CONTROL OF GENE THERAPY RESEARCH AND APPLICATION 
It is implicit in the establishment of your Committee that Society has an 
interest in regulating research and treatment by genetic modification. The 
issue is one of such magnitude and public interest that we would consider it 
inappropriate that it should be controlled by the existing Ethics 
Committees of Hospitals , Post Graduate Institutes or Universities. 
Although National Bodies such as the Royal Colleges clearly make a major 
contribution, particularly with their appreciation of scientific and medical 
issues, a more broadly based regulatory Body which fully reflects Society's 
interests needs to be established. 
There is also a need for National Governments to work with others 
towards international conventions. Work has already begun on this with 
the European Community. (Recommendation No . 934 (1982) on Genetic 
Engineering from the 33rd ordinary session of the Parliamentary Assembly 
of the Council of Europe.) 
We acknowledge that advances in molecular biology might perhaps lead 
to more extensive embryo screening in In Vitro Fertilisation programmes 
for an increasing number of inherited disorders. Within our moral 
tradition , however, there are particular difficulties in the use of In- Vitro 
Fertilisation as a method of reproduction. 
In- Vitro Fertilisation is not in accord with our view that the gift of life 
should normally come as a result of mutual self gift of parents. The role of 
third parties (as technician or as donor) in what can correctly be regarded as 
asexual reproduction has not been determined and we are concerned at the 
possibility that new life conceived in this way may be seen as a 'product' 
under human control. This in our tradition would not do full justice to the 
standing of the individual. It has always been our view that human life has 
an inestimable value which is not lost through sickness or aging or inborn 
imperfection. Furthermore, it has always been the Catholic position that 
human life demands respect from its first origins to its natural end (Domlln 
Vitae. Vatican Polyglot Press, 1988). 
There is here, perhaps , a further argument for a national Medical Ethics 
Committee with wide representation and public accountability. Such a 
Body should be answerable to Parliament through the Secretary of State 
and the proposed Licensing Authority for Embryology and Human 
Fertilisation could, with suitable amendments , be a model for such a 
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regulatory and licensing body. There is an obvious need for scientists of 
adequate standing to be advising this Body, but an equal need for advice 
from other traditions in Society including the main religious denominations 
and systematic philosophies as well as informed la y opinion . A regulatory 
Body would enjoy more public confidence if its composition was not 
predominantly medical and scientific . 
Society has a major interest in future developments of the manipulation 
of the human genome and a Regulatory Body could only properly be seen 
as accountable to Society if it were established on the authority of 
Parliament. 
II remains our conviction that H'hilst scientific ach'ancement is a 
legitimate objective in its mrn right, Il'hen applied to Man science must 
alwars remain at his service and that human dignitr remains paramount. 
We conclude, that somatic cell therapy will offer substantial benefits. 
suitably controlled. Germ line cell therapy, however. should no t be 
contemplated until somatic cell therapy has proved successful fora suitable 
length of time, perhaps one generation . We do not consider germ line cell 
therapy ethically justifiable at the present time. if ever. 
Signed hr 
NORFOLK 
President of the Catholic Union of' Great Britain 
J . C. GALLAGHER 
Master o f'the Guild of' Catholic Doc{()rs 
I. M . JESSI MAN 
Chairman of' the Joint £t hico- IHedical Co 111 111 ill 1'1' 
Th e Committee I\ 'ishes to record its appreciation {() Dr. A nthOn!' Cole, 
FRCPE. DCH. Il'ho ;I'rote the initial drafi of'this {JapeI'. 
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